HTRA2 also called Omi is a mammalian serine protease at high temperatures and has a chaperone activity at low temperature. The full-length HTRA2 is synthesized as a precursor protein and then targeted to the mitochondria where it is matured by the removal of N-terminal 133 residues. Mature HTRA2 consists of a putative transmembrane domain; an inhibitor of apoptosis protein (IAP)-binding motif; a single C-terminal PDZ domain that mediates protein-protein interactions. Recently, HTRA2 has known to contribute both to caspase-dependent and caspase-independent cell death.
Defects in HTRA2 are the cause of Parkinson disease type 13. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

The antibody is stable for at least 1 year from the date of receipt when stored at -20°C to -70°C. Reconstituted antibody can also be aliquotted and stored at 4°C for 1 month or at -20°C to -70°C in a manual defrost freezer for many months without detectable loss activity. Please avoid freeze-thaw cycles.

The antibody can specifically bind to its immunogen, and did not show any cross reactivity with unrelated antigens in ELISA. The specificity for binding to recombinant protein, cellular protein and native antigen is not defined. Cross reactivity with mouse and rat HTRA2 has not yet been tested.

Rabbit Anti-Human HTRA2 (C-terminus)(cat# DS-PB-02627) Custom Human HTRA2 ELISA Kit,(cat#ELH-HTRA2-001) Recombinant Human HTRA2 (cat#228-10807-3)